Chief Financial Officer

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Nuvalent Insider Sold Shares Worth $293,642, According to a Recent SEC Filing

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Nuvalent assumed with a Buy at Guggenheim

Director, Market Access Marketing

Nuvalent is an early-stage company focused on creating selective medicines for cancer patients. The Director of Market Access Marketing will execute the Market Access and Pricing strategy for their products, ensuring strategic positioning for payer access and collaborating with various teams to drive market success.

Sign up with Google

Sign in with Google